Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.

@article{Yang2009CosteffectivenessOL,
  title={Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.},
  author={Li Yang and Ming Li and Li-bo Tao and Mingliang Zhang and M Deborah Nicholl and Peng Dong},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2009},
  volume={12 Suppl 3},
  pages={S66-9}
}
OBJECTIVES To determine the most cost-effective strategy involving first-line treatment with long-acting risperidone, olanzapine, and quetiapine from the perspective of the Chinese health-care system. METHODS A decision analytical model was applied. The model used a time horizon of 2 years. The probabilities of treatment response of different agents and the relapse and hospitalization rates were estimated by a Delphi panel of 17 senior psychiatrists in China. The unit cost for each medical… CONTINUE READING

From This Paper

Topics from this paper.
7 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

An international review of the economic costs of mental

  • TW Hu
  • WHO,
  • 2008

An international review of the economic costs of mental illness

  • TW Hu
  • Update
  • 2008

The economic cost of schizophrenia [ in Chinese ]

  • Z Yang, ML Liu
  • Nurs Health Sci
  • 2007

Health Outcomes 2006;14:107–25

  • TM Si, L. Su
  • 2006

The survey on antipsychotic medication use in 10 provinces [ in Chinese ]

  • TM Si, L Su
  • Dis Manage Health Outcomes
  • 2006

2005;23(Suppl. 1):S1–2

  • NC Edwards, JC Locklear, MFT Rupnow
  • 2005

2005;23(Suppl. 1):S49–61

  • BM Heeg, G van Aalst, IJ van den Arend
  • 2005

A discrete events model of long - term outcomes and cost of treatment with long acting risperidone in schizophrenia

  • BM Heeg, G vanAalst, IJ vandenArend
  • Pharmacoeconomics
  • 2005

Similar Papers

Loading similar papers…